REG - Sareum Holdings PLC - Director/PDMR Shareholding

Sareum HoldingsAnnouncement

23/11/2021 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211123:nRSW3042Ta&default-theme=true

RNS Number : 3042T  Sareum Holdings PLC  23 November 2021

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Notification of transaction by Person Discharging Managerial Responsibilities
('PDMR')

Cambridge, UK, 23 November 2021 - Sareum Holdings plc (AIM: SAR), the
specialist drug development company delivering targeted small molecule
therapeutics to improve the treatment of cancer and autoimmune diseases,
announces that Dr Stephen Parker, Non-Executive Chairman, purchased 277,777
ordinary shares of 0.025 pence each in the capital of the Company at a price
of 3.6 pence per share on 23 November 2021.

The notification below, which has been made in accordance with the
requirements of the Market Abuse Regulation, provides further details.

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Stephen Parker
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman
 b)  Initial notification /Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Sareum Holdings plc
 b)  LEI                                                          213800PKERN2DY8FFM72
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 0.025p each in the share capital of Sareum Holdings plc

     Identification code                                          GB00B02RFS12

 b)  Nature of the transaction                                    Purchase of shares
 c)  Price(s) and volume(s)
                                                                                       Price(s)             Volume(s)
                                                                                       3.6 pence            277,777

 d)  Aggregated information

     - Aggregated volume                                          277,777 ordinary shares

     - Price                                                      3.6 pence per share

 e)  Date of the transaction                                      23 November 2021
 f)  Place of the transaction                                     London Stock Exchange (AIM)

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                          01223 497 700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                               020 3764 2341

 MEDiSTRAVA Consulting (Financial PR)

 Mark Swallow / David Dible                 020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHLXLFLFFLEFBQ